NYSE American USD

Armata Pharmaceuticals, Inc. (ARMP)

3.5100 +0.5100 (+17.00%)

At close: November 6 at 4:00:00 PM EST

3.4000 -0.1100 (-3.13%)

After hours: November 6 at 5:05:00 PM EST

Trade ARMP on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for ARMP

Previous Close 3.0000
Open 3.0000
Bid 1.3000 x 20000
Ask 3.9000 x 10000
Day's Range 3.0900 - 3.5100
52 Week Range 2.7500 - 14.9800
Volume 69,245
Avg. Volume 186,387
Market Cap (intraday) 130.509M
Beta (5Y Monthly) 1.63
PE Ratio (TTM) --
EPS (TTM) -5.2900
Earnings Date (est.) Nov 11, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 17.50
Moby Rating Neutral

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; and AP-PA03 for Pseudomonas aeruginosa. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. is a subsidiary of Innoviva, Inc.

www.armatapharma.com

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ARMP

44.11%

S&P 500 (^GSPC)

7.76%

1-Year Return

ARMP

38.85%

S&P 500 (^GSPC)

9.77%

3-Year Return

ARMP

52.61%

S&P 500 (^GSPC)

68.96%

5-Year Return

ARMP

11.14%

S&P 500 (^GSPC)

57.04%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q1 FY26

Revenue 789k

Earnings -115.35M

Profit Margin -14,619.26%

FY25

FY26

-120M

-100M

-80M

-60M

-40M

-20M

-10000.0%

-5000.0%

Analyst Price Targets

15.00

17.50 Average

3.5100 Current

20.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 9/23/2026

Analyst HC Wainwright & Co.

Rating Action Reiterates

Rating Buy

Price Action Maintains

Price Target 15 -> 15

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

0.00%
Return on Assets (ttm)

-25.83%
Return on Equity (ttm)

--
Revenue (ttm)

5.54M
Net Income Avi to Common (ttm)

-192.18M
Diluted EPS (ttm)

-5.2900

Balance Sheet and Cash Flow

Total Cash (mrq)

23.95M
Total Debt/Equity (mrq)

--
Levered Free Cash Flow (ttm)

-27.41M

TRVI Trevi Therapeutics, Inc.

14.33 +16.32%

HLSQ Tessera Defense and Homeland Security Inc.

0.1326 +12.81%

BCDA BioCardia, Inc.

0.8500 -0.90%

ARDS Aridis Pharmaceuticals, Inc.

0.0001 -50.00%

KRSA Korsana Biosciences, Inc.

31.05 +2.04%

U.S. markets closed

Armata Pharmaceuticals, Inc. (ARMP)

Trading disclosure

7.01%

-8.83%

-61.26%

-44.11%

-38.85%

-11.14%

-100.00%

Armata Pharmaceuticals, Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch